Torrent Pharmaceuticals enters into licensing and supply agreement with Zydus Lifesciences

10 Nov 2023 Evaluate

Torrent Pharmaceuticals and Zydus Lifesciences have entered into a licensing and supply agreement to co-market Saroglitazar Mg for the treatment of Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. As the only approved drug for NASH and NAFLD in the country, Saroglitazar Magnesium is likely to play a key role in managing and mitigating these progressive and prevalent liver disorders.

With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden and offers greater convenience for patients. Under the terms of this agreement, Torrent will have semi-exclusive rights to co-market the product in India under the brand name VORXAR. Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.


Torrent Pharma Share Price

3170.55 66.00 (2.13%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.